Targeting mitoNEET to reduce brain damage after a stroke
mitoNEET as a therapeutic target for mitigating ischemic brain injury following MCAO
This study is looking at how a special protein called mitoNEET can help protect brain cells during a stroke, and it aims to test a new treatment that might improve recovery and reduce damage to the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-10912765 on NIH RePORTER |
What this research studies
This research investigates how targeting a specific protein called mitoNEET can help protect brain cells from damage caused by ischemic strokes. The study focuses on understanding the role of mitochondria in brain injury and aims to develop a new treatment using a compound called NL-1, which has shown promise in improving brain function in animal models. By exploring how mitoNEET functions in the brain, the researchers hope to find ways to enhance recovery and reduce cell death following a stroke.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced an ischemic stroke and are in the acute phase of recovery.
Not a fit: Patients who have not suffered a stroke or have chronic neurological conditions unrelated to ischemic brain injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery outcomes for stroke patients.
How similar studies have performed: Previous research has shown that targeting mitochondrial dysfunction can lead to improvements in stroke recovery, suggesting that this approach has potential for success.
Where this research is happening
Morgantown, United States
- West Virginia University — Morgantown, United States (Active)
Researchers
- Principal investigator: Huber, Jason D — West Virginia University
- Study coordinator: Huber, Jason D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.